Table 4.
CVD mortality rates per 100 000 person-years in four population-based cohort studies in Iran, ages 40–65 years
| 10-year CVD mortality, n | Person-years | Crude mortality rate (95% CI) | Direct standardised mortality rate (95% CI)* | Direct standardised mortality rate (95% CI)† |
Multivariable adjusted HRs‡ | P values | |
| Total | |||||||
| TLGS | 66 | 42 787 | 158 (125 to 202) | 153 (115 to 191) | 183 (139 to 228) | 1 | – |
| ICS | 56 | 32 223 | 178 (137 to 231) | 173 (127 to 218) | 196 (144 to 249) | 1.17 (0.82–1.67) | 0.394 |
| GCS | 1080 | 3 61 418 | 303 (285 to 321) | 324 (304 to 344) | 366 (343 to 389) | 2.30 (1.79–2.96) | <0.001 |
| ShECS | 27 | 22 744 | 119 (82 to 174) | 118 (72 to 163) | 133 (81 to 184) | 0.85 (0.54–1.34) | 0.477 |
| Women | |||||||
| TLGS | 24 | 24 314 | 101 (68 to 150) | 95 (57 to 134) | 118 (71 to 165) | 1 | – |
| ICS | 20 | 16 641 | 123 (79 to 191) | 121 (68 to 175) | 131 (72 to 190) | 1.27 (0.70–2.29) | 0.434 |
| GCS | 540 | 2 13 755 | 256 (235 to 278) | 274 (251 to 298) | 316 (288 to 344) | 3.03 (2.01–4.59) | <0.001 |
| ShECS | 11 | 13 566 | 81 (45 to 147) | 76 (31 to 121) | 87 (34 to 139) | 1.02 (0.49–2.09) | 0.963 |
| Men | |||||||
| TLGS | 42 | 18 473 | 235 (174 to 318) | 211 (146 to 276) | 251 (175 to 328) | 1 | – |
| ICS | 36 | 15 582 | 236 (170 to 327) | 222 (148 to 296) | 262 (175 to 349) | 1.09 (0.70–1.71) | 0.693 |
| GCS | 540 | 1 47 663 | 371 (341 to 404) | 374 (342 to 406) | 426 (388 to 463) | 1.92 (1.38–2.63) | <0.001 |
| ShECS | 16 | 9178 | 175 (107 to 285) | 145 (74 to 215) | 173 (87 to 259) | 0.76 (0.42–1.36) | 0.353 |
*Age adjustment based on Iranian national census.
†Age adjustment based on ‘European’ standard population.
‡HRs based on Cox model adjusted by age, sex, hypertension, smoking, self-reported diabetes and body mass index.
CVD, cardiovascular disease; GCS, Golestan Cohort Study (phase 1); ICS, Isfahan Cohort Study; ShECS, Shahroud Eye Cohort Study; TLGS, Tehran Lipid and Glucose Study.